Adipose Tissue Blood Flow in Aging Humans

NCT06096532 | Recruiting

• 2 other identifiers: 23-004200UL1TR002377
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this basic science clinical trial is to understand whether adipose tissue blood flow changes between younger and older healthy adults. The main question\[s\] it aims to answer are:

• Is basal and nutrient responsive adipose tissue blood flow (ATBF) different between younger and older adults
• What molecular and systemic signatures related to adipose tissue blood flow are altered between these two groups. Participants will undergo measurements of adipose tissue blood flow using the xenon washout technique, undergo 2 abdominal subcutaneous adipose tissue biopsies, and drink a sugary drink.

Conditions

Healthy; Aging

Outcome Measures

Primary Outcomes (1)

• Adipose tissue blood flow

  blood flow will be measured in the upper body subcutaneous adipose tissue using 133 Xenon washout and reported as blood flow in ml/min/100g adipose tissue.

  Baseline, pre-intervention fasting and immediately following 75 gm oral glucose load

Secondary Outcomes (1)

• Genomic alterations

  Baseline, pre-intervention fasting and immediately following 75 gm oral glucose load

Study Arms (2)

Older Adults

OTHER

Other: 75 gm oral glucose load

Younger Adults

ACTIVE COMPARATOR

Other: 75 gm oral glucose load

Interventions

75 gm oral glucose load OTHER

Consumption of 75 gm oral glucose load in order to test nutrient responsiveness

Older Adults; Younger Adults

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Within the ages of 18-35 years or 65-80 years at time of study visit
• BMI between 20-25.0 kg/m2.

You may not qualify if:

• Presence of diagnosed cardiometabolic diseases (e.g., Type 2 diabetes, hypertension, Heart Failure)
• Taking prescription anticoagulants
• Taking prescriptions or supplements that effect adipose tissue metabolism (i.e., statins, Thiazolidinediones, niacin, atypical antipsychotics, or fish oil)
• Pregnant or nursing
• Inability to provide written informed consent
• Smokers

Sponsors & Collaborators

• Mayo Clinic: lead
• National Center for Advancing Translational Sciences (NCATS): collaborator

Study Sites (1)

Mayo Clinic Minnesota

Rochester, Minnesota, 55905, United States

RECRUITING

Related Links

• Mayo Clinic Clinical Trials

Study Officials

• Kelli Lytle, PhD

  Mayo Clinic

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: September 26, 2023
• First Posted: October 23, 2023
• Study Start: February 15, 2024
• Primary Completion (Estimated): December 30, 2028
• Study Completion (Estimated): December 30, 2028
• Last Updated: May 1, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)